Skip to main content

Study on Oral Medication, Selgantolimod, for Treating Hepatitis B in Participants With Both HIV and Chronic Hepatitis B

Research Question:
Is the oral medication, Selgantolimod, effective at treating Hepatitis B in people with chronic Hepatitis B and HIV?

Basic Study Information

This study will asses the safety of an oral medication, called Selgantolimod, which may help reduce the amount of hepatitis B virus in the blood. In this study, Selgantolimod will be given over a 6-month period to participants that are dually infected with HIV and chronic hepatitis B. Participants will need to have been taking suppressive antiviral therapy for both viruses - for at least the last 5 years - to be eligible.

Location: University of Rochester Adult HIV Therapeutic Strategies Network CRS
Study Reference #: STUDY00007918

Lead Researcher (Principal Investigator)

Lead Researcher:  Sonal Munsiff

Study Contact Information

Study Coordinator: Susan Hulse
Phone: (585) 275-0529

Additional Study Details

Study Details:
Individuals will be randomized to receive Selgantolimod or placebo. The medication will be taken as directly observed therapy one time per week for 24 weeks. The medication will require that the individual not eat for 8 hours before taking it and then 4 hours after.

Number of Visits:  More than 10
Parking:  Free
Transportation Coverage: 
Reimbursement:  Yes

Learn More About These Conditions

More information about Hepatitis B

More information about Hepatitis B, Chronic

More information about HIV Infections

More information about Human immunodeficiency virus [HIV] disease

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search